Clinical trials: Pacap-38
Migraine
To Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 in Migraine Patients
Phase I, Randomized, Parallel-group, Double-Blind, Placebo-Controlled, Single Dose Study to Evaluate the Blockade of CGRP Receptor by AMG 334 in Preventing PACAP-38 Induced Migraine-like Attacks in Migraine Patients.
- Trial name
- NCT02542605
- Testing
- Erenumab, PACAP-38 Challenge Agent
- Where
- 3 sites in United States, Belgium and 1 more
- Volunteers
- 35 people
- Sponsor
- Amgen